Allergan (AGN) Tops Q3 EPS by 10c; Issues Strong Q4, FY14 EPS Outlook

Allergan (NYSE: AGN) reported Q3 EPS of $1.78, $0.10 better than the analyst estimate of $1.68. Revenue for the quarter came in at $1.79 billion versus the consensus estimate of $1.78 billion.

Allergan sees FY2014 EPS of $6.27-$6.30, versus the consensus of $6.12. Allergan sees FY2014 revenue of $7.08-7.155 billion, versus the consensus of $7.15 billion.

Allergan sees Q3 2014 EPS of $1.80-$1.83, versus the consensus of $1.74. Allergan sees Q3 2014 revenue of $1.845-1.920 billion, versus the consensus of $1.87 billion.

For earnings history and earnings-related data on Allergan (AGN) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Genco rejects Diana Shipping takeover bid as undervalued
• Keefe, Bruyette & Woods Starts Columbia Financial Inc (CLBK) at Outperform